Trial-level timing alignment
Each session can preserve stimulus events, cue type, block context, saccadic timing, manual response timing, and validity indicators in a reviewable structure.
Clinical neurotechnology for objective cognition
Objective cognitive measurement for concussion care and beyond.
RetinaTek is building session-bounded, task-evoked measurement that aligns eye movement, pupil, manual-response, symptom, and stimulus-timing signals into a clearer view of neurocognitive performance.
The wedge
Concussion workflows still need better objective signal.
Many current workflows lean on symptoms, short cognitive screens, and single-modality tools. RetinaTek's approach focuses on how a person performs during controlled cognitive tasks, creating a path toward objective adjunctive support for assessment, recovery tracking, and research endpoints.
Data sophistication
Structured reports from controlled BEAM sessions.
RetinaTek does more than collect signals. Controlled sessions can be transformed into auditable outputs that connect stimulus events, gaze behavior, saccadic and manual response timing, pupil windows, validity indicators, and plain-English review summaries.
Multimodal quality context
Reports can pair gaze-derived measures with pupil windows, blink/data-quality signals, and structured behavioral codes instead of flattening the session into a single score.
Auditable export trail
Parser version, schema version, source integrity fields, and generated timestamps support diligence, repeatability, and controlled review workflows.
Evidence snapshot
Built from a scientific foundation, presented with conservative claims.
Public copy separates evidence-backed findings, planned regulatory milestones, and future platform concepts.
74.7%
Evidence-backed, scientific review
BEAM multimodal classifier
Reported in a chronic mTBI vs control cohort, with Nagelkerke R2 = 38%.
p=.011
Evidence-backed, scientific review
Longitudinal recovery tracking
VR+ cohort N=103 showed BEAM Saccadic Inhibition Errors changed more steeply in subacute mTBI than controls.
0/151
Evidence-backed, scientific review
VR tolerability signal
0/48 in a mobile-VR pilot and 0/103 in repeated VR+ exposures across the available source materials.
AUC 0.99
Evidence-backed, scientific review
Best-effort vs fake-bad responding
BEAM saccadic-validity index reported AUC 0.99 with 95% CI 0.96-1.00.
Scalable product architecture
One evidence base, multiple launch paths.
The site is structured around reusable product, evidence, milestone, and news modules so RetinaTek can add launches without rebuilding the marketing system.
RETINA Clinical
A VR headset-based multimodal SaMD pathway for clinician-supervised concussion evaluation, with adult, longitudinal, and adolescent regulatory milestones planned.
RETINA Research
A research-facing pathway for evidence generation, usability work, data-quality validation, and future substrate-aligned biomarker studies.
Cognitive Readiness
A future-facing concept for opt-in, task-based cognitive readiness, personal baselines, and educational interpretation. Consumer brand remains to be decided.
Regulatory roadmap
Planned milestones are labeled as targets, not clearances.
R61
Months 1-12
Device lock, FDA pre-submission, IRB, and healthy-volunteer pilots
Planned program milestone
R33
Months 13-48
Pivotal clinical enrollment, algorithm optimization, and regulatory evidence package
Planned program milestone
Adult 510(k)
Month 45 target
Initial adult filing target for aid in the assessment of concussion
Regulatory target, not clearance
Special 510(k)
Month 51 target
Longitudinal monitoring supplement target for aid in the management of concussion
Regulatory target, not clearance
Adolescent supplement
Month 54 target
Supplement target for ages 10-17 after adolescent validation
Regulatory target, not clearance
Important review note
RETINA is presented here as an in-development technology pathway. Website copy should receive scientific, regulatory, legal, and founder review before external launch.